GlassScriptPhysician profile
Eric S Langer
NPI 1720003718
$213,044.78
in general payments reported to CMS, 2019-2025
60 companies · $59K in 2025
The $59K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $22K · 2021: $22K · 2022: $18K · 2023: $8,413 · 2024: $8,172 · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $9,659 · Travel and Lodging: $6,860 · Consulting Fee: $1,200 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,893.75 |
| Food and Beverage | $9,658.78 |
| Travel and Lodging | $6,859.55 |
| Consulting Fee | $1,200.00 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110,259.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ascendis Pharma Endocrinology INC | $60,462.69 | 2022-2025 | Yorvipath |
| Ibsa Pharma INC. | $9,953.77 | 2019-2025 | Tirosint, Licart, Flector |
| Janssen Pharmaceuticals, INC | $7,508.43 | 2019-2020 | |
| Medtronic Minimed, INC. | $4,211.32 | 2019-2020 | |
| Medtronic, INC. | $3,220.29 | 2021-2025 | Minimed 780g, Accurian, Minimed 770g |
| Senseonics, Incorporated | $2,237.00 | 2019-2020 | |
| Amgen INC. | $1,253.68 | 2019-2025 | Evenity, Repatha, Tepezza |
| Lilly USA, LLC | $1,187.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,111.94 | 2019-2025 | |
| Dexcom, INC. | $857.23 | 2019-2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $854.30 | 2022-2025 | |
| Abbvie INC. | $815.57 | 2019-2025 | |
| Insulet Corporation | $778.72 | 2019-2022 | |
| Abbott Laboratories | $752.43 | 2019-2025 | Freestyle Libre 3 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $704.71 | 2019-2024 | Farxiga |
| Mannkind Corporation | $648.71 | 2019-2025 | Afrezza |
| Amneal Pharmaceuticals LLC | $521.49 | 2019-2025 | Unithroid |
| Amarin Pharma, INC. | $521.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.14 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $425.81 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Lifescan, INC. | $397.60 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $344.65 | 2021-2024 | |
| Radius Health, INC. | $343.10 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $330.73 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $318.71 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $259.55 | 2024-2025 | |
| Antares Pharma, INC. | $193.26 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Recordati_rare_diseases_inc. | $190.55 | 2020-2025 | Isturisa, Signifor Lar |
| Sequel Med Tech, LLC | $164.50 | 2025 | Twiist |
| Becton, Dickinson and Company | $150.19 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $148.92 | 2019-2025 | Strensiq |
| Zealand Pharma US, INC. | $119.74 | 2021-2022 | |
| Alvogen INC | $118.93 | 2022-2025 | Teriparatide |
| Tandem Diabetes Care, INC. | $117.73 | 2019-2020 | |
| Valeritas, INC. | $114.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.05 | 2019-2020 | |
| Shire North American Group INC | $88.14 | 2019 | |
| Amryt Pharma Holdings LTD | $84.24 | 2022-2023 | Mycapssa |
| Eusa Pharma (US) LLC | $82.68 | 2022 | |
| Madrigal Pharmaceuticals | $58.68 | 2025 | Rezdiffra |
| Pfizer INC. | $50.54 | 2019-2023 | |
| Cequr Corporation | $49.97 | 2024-2025 | Cequr Simplicity |
| Chiesi USA, INC. | $39.07 | 2024 | Juxtapid, Mycapssa |
| Glaxosmithkline, LLC. | $37.29 | 2025 | Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $33.71 | 2021-2022 | |
| Embecta Corp. | $29.74 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Takeda Pharmaceuticals U.S.A., INC. | $29.23 | 2020 | |
| Horizon Therapeutics Plc | $27.89 | 2020-2022 | |
| Eisai INC. | $27.48 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $25.56 | 2025 | Imcivree |
| Clarus Therapeutics INC. | $23.85 | 2021 | |
| Nevro Corp. | $21.70 | 2022 | |
| Intra-Sana Laboratories | $21.19 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Averitas Pharma INC. | $20.77 | 2023 | Qutenza |
| Ultragenyx Pharmaceutical INC. | $18.16 | 2022 | |
| Companion Medical, INC. | $17.18 | 2020 | |
| Endo Pharmaceuticals INC. | $16.78 | 2022 | |
| Alfasigma USA, INC. | $15.60 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.